enGene announced that Theresa Podrebarac, has been appointed as the Chief Medical Officer of the company. He will be responsible for designing and executing clinical development plan for enGene’s pipeline of products, as well as effectively positioning these novel therapeutics in the marketplace.
Dr. Podrebarac is a 15-year industry veteran with extensive pharmaceutical drug development expertise from large pharma and biotech companies. She joins enGene from AbbVie where she served as VP, Immunology Clinical Development. At AbbVie, she led the Immunology Therapeutic Council to develop the future vision for the company’s portfolio and introduced integrated biomarker techniques and quantitative decision tools to early clinical development. Previously, she was VP of Early Clinical Development and Immunology at Biogen, where she successfully led the strategy to develop several compounds in autoimmune and fibrotic diseases. She has also supported the approvals of Tysabri for multiple sclerosis, Rituxan for rheumatoid arthritis, and championed the development of tools and techniques for early clinical proof of concept in diseases including inflammatory bowel disease. Prior to Biogen, Dr. Podrebarac served as VP and Head of Rheumatology Global Clinical Development at EMD Serono where she led a global team of physicians and scientists within the clinical development unit and provided strategic leadership to the Autoimmunity, Inflammation and Emerging Therapies Unit.
Dr. Podrebarac is a board certified rheumatologist who earned her medical degree from the University of Western Ontario and completed post-doctoral training in T cell immunology at Harvard University and Brigham and Women’s Hospital in Boston.